GPCR/G protein

All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
-  
C3572 JD5037Summary: inverse agonist at CB1 receptors -  
B1477 Lurasidone HClTarget: 5-HT2 Receptors|D2 Receptors|5-HT1 Receptors|5-HT7 ReceptorsSummary: Dopamine D2/5-HT2A/5-HT7/5-HT1A inhibitor -  
B1343 Phenoxybenzamine HClSummary: Adrenergic receptor antagonist -  
B6926 PSB 36Summary: A1 adenosine receptor antagonist -  
C3568 (S)-SLV 319Summary: CB1 receptor antagonist -  
B1206 PizotifenTarget: 5-HT2 ReceptorsSummary: Highly selective 5-HT receptor blocking agent -  
B1342 Oxymetazoline HClSummary: Alpha-1/alpha-2 agonist -  
B6924 PSB 11 hydrochlorideSummary: human adenosine A3 receptor antagonist -  
C3493 AM4113Summary: cannabinoid receptor 1 (CB1)-selective neutral antagonist -  
B1205 FluvoxamineTarget: Serotonin reuptakeSummary: Selective serotonin reuptake inhibitor 
